Write in a clean editor, then format for Obesity Pillars in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Obesity Pillars is a peer-reviewed journal published by Elsevier, covering Bariatric Surgery and Outcomes, Obesity and Health Practices, Pharmacology and Obesity Treatment.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, Obesity Pillars 12 (2023) 45–58.
Formats any DOI in Obesity Pillars style. No sign-up. |
| Publishes research in | Bariatric Surgery and Outcomes Obesity and Health Practices Pharmacology and Obesity Treatment Obesity, Physical Activity, Diet Diabetes Treatment and Management |
| ISSN | 2667-3681 |
| Citation impact (2-yr) | 4.15 |
| h-index | 24 |
| i10-index | 64 |
| Total citations | 2,361 |
| Open access | Yes |
| Top institutions publishing here | Louisville Metabolic and Atherosclerosis Research Center |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
The Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) regarding definition, diagnosis, bias, standard operating procedures (SOPs) and telehealth is intended to provide clinicians an overview of obesity medicine and provide basic organizational tools towards establishing, directing, managing, and maintaining an obesity medical practice. This CPS is based upon published scientific citations, clinical perspectives of…
Background: This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) provides clinicians an overview of Artificial Intelligence, focused on the management of patients with obesity. Methods: The perspectives of the authors were augmented by scientific support from published citations and integrated with information derived from search engines (i.e., Chrome by Google, Inc) and chatbots (i.e.,…
This review investigates the side effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) like liraglutide, semaglutide, and tirzepatide, medications known for their efficacy in promoting weight loss among individuals with obesity. The rationale is rooted in understanding the balance between their therapeutic benefits and associated risks. This was a comprehensive clinical review, including systematic reviews, meta-analyses,…
Objective: Binge eating disorder (BED) is the most common eating disorder, and yet only one pharmacotherapy (lisdexamfetamine), which has known abuse-potential, is FDA-approved. Topiramate is also commonly prescribed off-label for binge eating but has many contraindications. In contrast, the glucagon-like peptide-1 (GLP1) analog semaglutide has profound effects on central satiety signaling leading to reduced food…
Background: This "Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association Clinical Practice Statement 2022" is intended to provide clinicians an overview of Food and Drug Administration (FDA) approved anti-obesity medications and investigational anti-obesity agents in development. Methods: The scientific information for this Clinical Practice Statement (CPS) is based upon published scientific citations, clinical perspectives…
